Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

ASCO Daily News

In men with metastatic hormone-sensitive prostate cancer (mHSPC), the addition of enzalutamide to testosterone suppression continues to provide a significant improvement in overall survival (OS) after more than 5 years, according to an update from the phase 3 ENZAMET trial presented by Ian D. Davis, MBBS, PhD, FRACP, FAChPM, of Monash University and Eastern Health, in Australia, during the 2022...

  • 123456 Profile photo of Madelyn

    Doublet therapy is here to stay for mHSPC – updated OS presented from ENZAMET.